Thiard News@F4F

@newsen.bsky.social

3 hours ago

Faruqi & Faruqi Alerts Investors About RGNX Class Action Lawsuit Deadline Faruqi & Faruqi, LLP is reminding investors in REGENXBIO (RGNX) about the approaching deadline for filing claims related to the company's class action lawsuit.

Faruqi & Faruqi Alerts Investors About RGNX Class Action Lawsuit Deadline #USA #New_York #Faruqi_&_Faruqi #REGENXBIO #RGNX

Thiard News@F4F

@newsen.bsky.social

19 hours ago

Opportunities for RGNX Investors to Join REGENXBIO Securities Fraud Litigation REGENXBIO investors can seize an opportunity to lead a securities fraud lawsuit. Important deadline approaching for class action participation.

Opportunities for RGNX Investors to Join REGENXBIO Securities Fraud Litigation #USA #New_York #Rosen_Law_Firm #REGENXBIO #RGNX

Thiard News@F4F

@newsen.bsky.social

20 hours ago

Robbins LLP Urges REGENXBIO Shareholders to Know Their Rights Amid Class Action Robbins LLP has announced a class action for REGENXBIO investors, encouraging them to understand their rights and potential claims regarding recent allegations.

Robbins LLP Urges REGENXBIO Shareholders to Know Their Rights Amid Class Action #United_States #San_Diego #Robbins_LLP #REGENXBIO #RGNX

Thiard News@F4F

@newsen.bsky.social

1 week ago

Pomerantz Law Firm Alerts Investors of Class Action Against REGENXBIO Inc. - Important Deadlines Approaching Pomerantz Law Firm notifies investors of possible securities fraud linked to REGENXBIO Inc. Class action lawsuit filed, deadlines imminent.

Pomerantz Law Firm Alerts Investors of Class Action Against REGENXBIO Inc. - Important Deadlines Approaching #USA #New_York #Pomerantz #REGENXBIO #RGNX

StockTitan

@stocktitan.net

1 week ago

SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD {"summary":"","positive":[],"negative":[],"faq":[]}

#RGNX SUEWALLST, LLP: INSTITUTIONAL RGNX HOLDERS FACE PORTFOLIO LOSSES FROM GENE THERAPY FRAUD

www.stocktitan.net/news/RGNX/suewallst-llp-...

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

Important Notice for REGENXBIO Investors on Securities Class Action Deadline by Faruqi & Faruqi Faruqi & Faruqi, LLP is reminding investors of REGENXBIO about a critical securities class action deadline on April 14, 2026. Investors should act now.

Important Notice for REGENXBIO Investors on Securities Class Action Deadline by Faruqi & Faruqi #USA #New_York #Faruqi_&_Faruqi #REGENXBIO #RGNX

Thiard News@F4F

@newsen.bsky.social

2 weeks ago

RGNX Shareholders May Pursue Class Action Against REGENXBIO Inc. for Misleading Information Shareholders of REGENXBIO Inc. (NASDAQ: RGNX) are encouraged to seek leadership positions in a class action lawsuit due to alleged misleading communications by the company.

RGNX Shareholders May Pursue Class Action Against REGENXBIO Inc. for Misleading Information #USA #New_York #Class_Action #REGENXBIO #RGNX

Thiard News@F4F

@newsen.bsky.social

3 weeks ago

Investors Can Step Forward in REGENXBIO Securities Fraud Case The Rosen Law Firm invites investors of REGENXBIO, Inc. to participate in a securities fraud lawsuit regarding RGX-111. The deadline is April 14, 2026.

Investors Can Step Forward in REGENXBIO Securities Fraud Case #USA #New_York #Securities_Fraud #REGENXBIO #RGNX

Thiard News@F4F

@newsen.bsky.social

3 weeks ago

Pomerantz Law Firm Warns Investors About Class Action Lawsuit Against REGENXBIO Inc. Pomerantz Law Firm has filed a class action against REGENXBIO Inc. following allegations of securities fraud. Investors have upcoming deadlines to participate.

Pomerantz Law Firm Warns Investors About Class Action Lawsuit Against REGENXBIO Inc. #USA #New_York #Pomerantz #REGENXBIO #RGNX

StockTitan

@stocktitan.net

3 weeks ago

REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 Investigational RGX-202 continues to demonstrate evidence of positively changing disease trajectory for Duchenne Pivotal dose participants exceeded external controls across functional measures at 1 year, including participants aged 8+ Cardiac MRI data for pivotal dose patients demonstrated stability at 1 year Favorable safety profile continued...

#RGNX REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202

www.stocktitan.net/news/RGNX/regenxbio-repo...

Thiard News@F4F

@newsen.bsky.social

3 weeks ago

Investors of REGENXBIO Inc. Urged to Join Class Action Lawsuit for Recovering Losses Investors who faced financial losses with REGENXBIO Inc. can join a class action lawsuit led by Levi & Korsinsky to recover damages related to alleged securities fraud.

Investors of REGENXBIO Inc. Urged to Join Class Action Lawsuit for Recovering Losses #United_States #New_York #Levi_&_Korsinsky #REGENXBIO #RGNX

Thiard News@F4F

@newsen.bsky.social

3 weeks ago

Opportunity for RGNX Investors to Lead REGENXBIO Class Action Lawsuit REGENXBIO, Inc. investors can join a class action lawsuit for compensation regarding securities fraud. Important deadlines approaching.

Opportunity for RGNX Investors to Lead REGENXBIO Class Action Lawsuit #United_States #New_York #Securities #REGENXBIO #RGNX

StockTitan

@stocktitan.net

4 weeks ago

REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights Late-stage gene therapy pipeline for rare and retinal diseases advancing toward key catalysts RGX-202 for Duchenne muscular dystrophy: New Phase I/II data at MDA, topline pivotal results expected early Q2 2026 Robust patient enrollment continues in confirmatory trial Surabgene lomparvovec subretinal wet AMD topline pivotal data expected in Q4 2026;...

#RGNX REGENXBIO Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights

www.stocktitan.net/news/RGNX/regenxbio-repo...

StockTitan

@stocktitan.net

1 month ago

REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference REGENXBIO (Nasdaq: RGNX) announced presentations on its investigational Duchenne gene therapy RGX-202 at the 2026 Muscular Dystrophy Association Clinical & Scientific Conference in Orlando, March 8-11, 2026.Events include an interim Phase I/II podium presentation on March 11, a preclinical poster, and a company-hosted symposium on March 9 at 12 p.m. ET. Presentation materials will be posted in the company's Publications section.

#RGNX REGENXBIO Announces Presentations at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference

www.stocktitan.net/news/RGNX/regenxbio-anno...

Thiard News@F4F

@newsen.bsky.social

1 month ago

Rosen Law Firm Encourages RGNX Investors to Take Action in Securities Fraud Case Investors in REGENXBIO, Inc. are reminded of their rights regarding a securities fraud lawsuit led by Rosen Law Firm, with a crucial deadline approaching.

Rosen Law Firm Encourages RGNX Investors to Take Action in Securities Fraud Case #United_States #New_York #Rosen_Law_Firm #REGENXBIO #RGNX

Thiard News@F4F

@newsen.bsky.social

1 month ago

Class Action Lawsuit Filed Against REGENXBIO: Stockholders Urged to Act Quickly Investors in REGENXBIO, Inc. are encouraged to join the class action lawsuit over financial losses linked to misleading claims about their drug candidate RGX-111.

Class Action Lawsuit Filed Against REGENXBIO: Stockholders Urged to Act Quickly #United_States #San_Diego #Robbins_LLP #REGENXBIO #RGNX

Thiard News@F4F

@newsen.bsky.social

1 month ago

Opportunity for RGNX Investors to Lead Class Action Against REGENXBIO Inc. Alleging Securities Fraud Investors in REGENXBIO Inc. have a chance to lead a class action lawsuit over alleged securities fraud facilitated by the Schall Law Firm. Learn how to participate!

Opportunity for RGNX Investors to Lead Class Action Against REGENXBIO Inc. Alleging Securities Fraud #USA #Los_Angeles #Schall_Law_Firm #REGENXBIO #RGNX

Thiard News@F4F

@newsen.bsky.social

1 month ago

REGENXBIO Inc. Faces Class Action Lawsuit Over Securities Law Violations Investors are reminded of a class action lawsuit against REGENXBIO Inc. for breaching securities laws, highlighting troubling statements regarding product safety.

REGENXBIO Inc. Faces Class Action Lawsuit Over Securities Law Violations #USA #Los_Angeles #Securities_Law #REGENXBIO #RGNX

Thiard News@F4F

@newsen.bsky.social

1 month ago

Investors Should Review Class Action Against REGENXBIO Inc. for Alleged Securities Fraud Pomerantz Law Firm has initiated a class action lawsuit against REGENXBIO Inc., concerning potential securities fraud. Investors should act promptly by the April 2026 deadline.

Investors Should Review Class Action Against REGENXBIO Inc. for Alleged Securities Fraud #United_States #New_York #REGENXBIO #RGNX #PomerantzLaw

Thiard News@F4F

@newsen.bsky.social

1 month ago

Important Notice to REGENXBIO Shareholders: Lead Plaintiff Deadline Approaches The Gross Law Firm informs REGENXBIO shareholders of a crucial lead plaintiff deadline set for April 14, 2026, regarding their latest lawsuit.

Important Notice to REGENXBIO Shareholders: Lead Plaintiff Deadline Approaches #USA #New_York #Gross_Law_Firm #REGENXBIO #RGNX

Thiard News@F4F

@newsen.bsky.social

1 month ago

Class Action Lawsuit Filed Against REGENXBIO Inc. Over Securities Violations A class action has been initiated against REGENXBIO Inc. concerning alleged violations of securities laws. Investors with losses are urged to participate.

Class Action Lawsuit Filed Against REGENXBIO Inc. Over Securities Violations #United_States #DJS_Law_Group #Eastchester #REGENXBIO #RGNX

Thiard News@F4F

@newsen.bsky.social

1 month ago

Regenxbio Faces Class Action Lawsuit Over Securities Violations Amid Investor Concerns Investors raise alarms as Regenxbio Inc. is sued for allegedly misleading statements regarding its RGX-111 product. Class action info included.

Regenxbio Faces Class Action Lawsuit Over Securities Violations Amid Investor Concerns #USA #Los_Angeles #DJS_Law_Group #REGENXBIO #RGNX

Thiard News@F4F

@newsen.bsky.social

1 month ago

Gross Law Firm Alerts REGENXBIO Investors About Class Action Lawsuit and Critical Deadline The Gross Law Firm is informing REGENXBIO Inc. shareholders about a class action lawsuit and an impending deadline that could be crucial for their investments.

Gross Law Firm Alerts REGENXBIO Investors About Class Action Lawsuit and Critical Deadline #USA #New_York #Gross_Law_Firm #REGENXBIO #RGNX

Thiard News@F4F

@newsen.bsky.social

1 month ago

Pomerantz Law Firm Investigates Claims Against REGENXBIO Investors - What You Need to Know Pomerantz Law Firm is delving into potential securities fraud claims related to REGENXBIO Inc. This article discusses the implications for investors.

Pomerantz Law Firm Investigates Claims Against REGENXBIO Investors - What You Need to Know #United_States #New_York #Pomerantz_Law #REGENXBIO #RGNX

Thiard News@F4F

@newsen.bsky.social

2 months ago

Concerns Raised Over Regenxbio's Disclosure Before FDA's Surprising Hold on Clinical Programs Levi & Korsinsky, LLP investigates Regenxbio Inc. amid questions regarding the transparency of investor information before regulatory setbacks in their clinical trials.

Concerns Raised Over Regenxbio's Disclosure Before FDA's Surprising Hold on Clinical Programs #USA #New_York #FDA_Hold #Regenxbio_Inc. #RGNX

StockTitan

@stocktitan.net

2 months ago

REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program REGENXBIO (Nasdaq: RGNX) reported positive long-term Phase I/II RGX-202 functional data for Duchenne, with treated patients improving an average of 7.4 NSAA points versus cTAP at 18 months (n=4) and 6.6 points at 12 months. The company expects pivotal topline data in early Q2 2026 and plans a mid-2026 BLA filing under accelerated approval while continuing confirmatory enrollment. REGENXBIO also highlighted an FDA PDUFA date of Feb 8, 2026

#RGNX REGENXBIO Highlights Key 2026 Catalysts and Announces Positive Long-Term Functional Outcomes in Lead Duchenne Gene Therapy Program

www.stocktitan.net/news/RGNX/regenxbio-high...

StockTitan

@stocktitan.net

4 months ago

REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights REGENXBIO (Nasdaq: RGNX) reported Q3 2025 results and operational milestones on November 6, 2025. Key clinical timelines include RGX-202 (Duchenne) topline expected early Q2 2026 with a planned BLA submission mid-2026, and RGX-121 (MPS II) with an FDA PDUFA date of February 8, 2026. Enrollment completed for the RGX-202 pivotal trial (n=30) and for sura-vec wet AMD pivotal trials (>1,200 participants); sura-vec wet AMD topline expected Q4 2026. Financials: cash $302.0M (Sept 30, 2025), revenues $29.7M Q3, R&D $56.1M Q3, and net loss $61.9M Q3. The company expects cash to fund operations into early 2027. Commercial manufacturing batches for RGX-202 were produced and process qualification is near completion.

#RGNX REGENXBIO Reports Third Quarter 2025 Financial Results and Operational Highlights

www.stocktitan.net/news/RGNX/regenxbio-repo...

StockTitan

@stocktitan.net

5 months ago

REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program REGENXBIO (Nasdaq: RGNX) completed enrollment in the pivotal AFFINITY DUCHENNE trial for RGX-202 in October 2025 and has manufactured the first batches intended for commercial supply at its Rockville Manufacturing Innovation Center.Key facts: pivotal enrollment = 30 participants; Phase I/II microdystrophin range 20%–122%; no SAEs or AESIs reported as of May 7, 2025; capacity = 2,500 doses/year; topline pivotal data expected in early Q2 2026 with a BLA submission targeted for mid-2026, and potential commercial launch in 2027.

#RGNX REGENXBIO Announces Completion of Pivotal Enrollment and Initiates Commercial Production in Duchenne Gene Therapy Program

www.stocktitan.net/news/RGNX/regenxbio-anno...

StockTitan

@stocktitan.net

5 months ago

REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting REGENXBIO (Nasdaq: RGNX) will present interim Phase II ALTITUDE trial data on suprachoroidal delivery of surabgene lomparvovec (sura-vec, ABBV-RGX-314) for diabetic retinopathy at the American Academy of Ophthalmology 2025 Annual Meeting. The presentation reports first-time 2-year results in non-proliferative diabetic retinopathy and is delivered by Charles C. Wykoff, M.D., PhD during Section IX: Late breaking developments, part I.Presentation date/time: October 17, 2025 at 4:46 p.m. ET. Sura-vec is an investigational one-time gene therapy developed in collaboration with AbbVie for wet AMD and DR.

#RGNX REGENXBIO Announces Presentation at the American Academy of Ophthalmology 2025 Annual Meeting

www.stocktitan.net/news/RGNX/regenxbio-anno...

StockTitan

@stocktitan.net

5 months ago

REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD REGENXBIO (Nasdaq: RGNX) announced completion of enrollment in the ATMOSPHERE and ASCENT pivotal trials of subretinal surabgene lomparvovec for wet age-related macular degeneration (wet AMD).Combined enrollment exceeded 1,200 participants across >200 sites worldwide, making this the largest global gene therapy program reported for an ocular indication. ATMOSPHERE (U.S.) compares sura-vec to ranibizumab; ASCENT (U.S. + 13 countries) compares sura-vec to aflibercept. Primary endpoints are non-inferiority in BCVA at 54 weeks and one year. Company cites durable effects up to 4 years in long-term follow-up and no drug-related serious adverse events in a 60-patient Phase II study. Topline pivotal data expected Q4 2026.

#RGNX REGENXBIO Announces Completion of Enrollment in Pivotal Trials of Subretinal Surabgene Lomparvovec for Wet AMD

www.stocktitan.net/news/RGNX/regenxbio-anno...